del Campo JM, Matulonis UA, Malander S, et al. - Given that a prolonged progression-free survival was achieved with maintenance therapy with niraparib, a poly(ADP-ribose) polymerase inhibitor, in patients with platinum-sensitive, recurrent ovarian cancer, who had a response to their last platinum-based chemotherapy, examined in the ENGOT-OV16/NOVA trial, researchers evaluated the clinical benefit as well as patient-reported outcomes in those who had a partial response (PR) and complete response (CR) to their last platinum-based treatment. Enrolled patients were 553 in total. A germline BRCA mutation (gBRCAmut) was present in 203 patients, of these, a PR and a CR to their last platinum-based therapy was reported in 99 and 104, respectively; of 350 patients without a proved gBRCAmut (non–gBRCAmut), a PR and a CR was achieved in 173 and in 177, respectively. In both the gBRCAmut cohort and the non–gBRCAmut cohort, improved progression-free survival was observed in relation to treatment with niraparib vs placebo. Overall, maintenance therapy with niraparib provided clinical benefit to patients irrespective of response to the last platinum-based therapy.